TLXTelix Pharma

Telix Pharmaceuticals shares fell sharply after announcing a major US$1.65 billion acquisition of ITM Isotope Technologies, with investors reacting negatively to the scale and cost of the deal.

The ASX Health Care sector rose strongly on the same day, lifting TLX as part of a broad sector rotation into health stocks.

TLX fell sharply in sympathy with a broader US market sell-off and weakness in the Australian healthcare sector, with no company-specific news to explain the move.

Positive analyst commentary and sector flows into ASX healthcare names, with Telix highlighted as a recovering growth share, likely drove the move.

The stock drop was part of a broader selloff in ASX 200 shares, with Telix Pharmaceuticals among the biggest losers for the day.

Telix Pharmaceuticals announced a radiopharma collaboration with Regeneron, a multi-billion dollar deal, driving the share price up 7.72%.

Telix Pharmaceuticals shares rose on the announcement of a major radiopharma partnership with Regeneron, including a $40 million upfront payment.

Telix Pharmaceuticals shares continued to bounce off lows, likely driven by a positive analyst mention and biotech sector interest despite a recent FDA-related drop.

Telix shares bounced off lows after a recent drop, despite a favorable US FDA update that was followed by buying interest.

Positive Phase 3 trial results for Telix's prostate cancer therapy triggered the stock surge.

Telix Pharmaceuticals shares fell 5.12% on March 8, 2026, ahead of the positive Phase 3 trial results announced on March 10, likely due to profit-taking or de-risking ahead of the binary readout.

Telix's expansion of its AI-driven imaging push, highlighted in a research partnership announced on the event date, likely drove the stock up.

Telix Pharmaceuticals' shares surged following strong 2026 guidance, a shelf filing, and a TLX101-Px milestone, as reported in news articles around the date.

Despite positive news of 2026 guidance, a shelf filing, and a TLX101-Px milestone, the stock fell 6.04% on the event date.

Telix Pharmaceuticals shares fell after a significant rally on Friday following FY25 results, likely due to profit-taking and market digestion of the news.

Telix Pharmaceuticals shares jumped 14.24% after reporting strong FY2025 results with 56% revenue growth and a positive FY2026 outlook.

Telix Pharmaceuticals fell amid a broad market downturn that pushed 13 ASX 200 stocks to multi-year lows, with no stock-specific adverse news.

Telix Pharmaceuticals shares bounced off multi-year lows amid broader ASX 200 market momentum and mention as a potentially undervalued stock, with no company-specific catalyst identified.

The stock fell sharply following a prior 55% sell-off, despite emerging China regulatory progress and positive full-year guidance updates.

Telix Pharmaceuticals fell 6.61% on December 16, 2025, due to news of a potential US class action lawsuit over alleged disclosure failings, exacerbating an ongoing steep decline.

No direct news found; likely driven by positive sector sentiment in healthcare or a company-specific announcement not captured in the provided articles.

No direct news explaining the price drop; likely unrelated to the reported collaboration announcement.

Telix Pharmaceuticals announced a collaboration with IMRA Surgical to advance radio-guided surgery education and training.

No news articles were found to explain the price movement; cause is undetermined.

Telix Pharmaceuticals shares plunged after the FDA requested more data on its cancer diagnostic drug, Pixclara.

Telix Pharmaceuticals released strong half-year results for 2025, highlighting robust commercial performance.

No direct cause found in news; likely due to a sector-wide healthcare selloff or market factors.

Telix Pharmaceuticals shares plunged 16% on July 23, 2025, likely due to a negative company-specific development, though the specific driver is not detailed in the limited news available.

No direct news for TLX.AX on the date; likely sector or market-wide movement or unannounced company-specific event.

Telix Pharmaceuticals faced a setback in US drug approval amid FDA workforce cuts, triggering a -6.58% share price decline.

No specific cause identified from available news articles.

Co-founders sold $118 million in shares, weighing on investor sentiment.

Telix Pharmaceuticals reported strong 2024 full-year results and issued FY2025 revenue guidance up to $1.23 billion, driving the share price up.

Telix Pharmaceuticals announced the acquisition of RLS to expand its North American manufacturing and distribution platform, driving the stock up.

Telix Pharmaceuticals announced a A$600 million convertible bonds offering, likely causing dilution concerns and a stock price drop.

A prominent fund manager publicly credited Telix Pharmaceuticals as a key driver of significant portfolio returns.